EA200501846A1 - Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом - Google Patents

Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом

Info

Publication number
EA200501846A1
EA200501846A1 EA200501846A EA200501846A EA200501846A1 EA 200501846 A1 EA200501846 A1 EA 200501846A1 EA 200501846 A EA200501846 A EA 200501846A EA 200501846 A EA200501846 A EA 200501846A EA 200501846 A1 EA200501846 A1 EA 200501846A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
treatment
growth
factor
defects associated
Prior art date
Application number
EA200501846A
Other languages
English (en)
Russian (ru)
Other versions
EA009390B1 (ru
Inventor
Алексис Карон
Флоренс Эмманюэль
Анна Карон
Франсуаза Финьельс
Сандрин Мишле
Бертран Шварц
Дидье Руй
Дидье Бранеллек
Original Assignee
Сентельон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентельон filed Critical Сентельон
Publication of EA009390B1 publication Critical patent/EA009390B1/ru
Publication of EA200501846A1 publication Critical patent/EA200501846A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200501846A 2003-06-05 2004-06-04 Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом EA200501846A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47595903P 2003-06-05 2003-06-05
US56091504P 2004-04-09 2004-04-09
US56619304P 2004-04-28 2004-04-28
PCT/EP2004/006903 WO2004108167A1 (en) 2003-06-05 2004-06-04 Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects

Publications (2)

Publication Number Publication Date
EA009390B1 EA009390B1 (ru) 2007-12-28
EA200501846A1 true EA200501846A1 (ru) 2007-12-28

Family

ID=33514717

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501846A EA200501846A1 (ru) 2003-06-05 2004-06-04 Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом

Country Status (11)

Country Link
US (1) US20050096286A1 (enExample)
EP (1) EP1677831A1 (enExample)
JP (1) JP2006526592A (enExample)
KR (1) KR20060052692A (enExample)
AU (2) AU2004244756A1 (enExample)
BR (1) BRPI0410844A (enExample)
CA (1) CA2526792A1 (enExample)
EA (1) EA200501846A1 (enExample)
NO (1) NO20060032L (enExample)
NZ (1) NZ543717A (enExample)
WO (1) WO2004108167A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2573896C2 (ru) * 2009-10-15 2016-01-27 Дженентек, Инк. Химерные факторы роста фибробластов с измененной рецепторной специфичностью

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7038026B2 (en) 2000-05-26 2006-05-02 Centelion Purification of a triple heli formation with an immobilized oligonucleotide
US7279313B2 (en) 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2822476B1 (fr) 2001-03-23 2004-04-02 Aventis Pharma Sa Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
JP2007536909A (ja) * 2003-12-29 2007-12-20 センテリオン 冠動脈または末梢性虚血の治療
JP2009532326A (ja) * 2006-02-09 2009-09-10 サンガモ バイオサイエンシーズ， インコーポレイテッド ジンクフィンガータンパク質により末梢動脈疾患を処置するための方法
JP5767314B2 (ja) 2010-04-16 2015-08-19 ソーク インスティチュート フォー バイオロジカル スタディーズ Ｆｇｆを用いて代謝障害を処置するための方法
SG11201603134XA (en) 2013-10-21 2016-05-30 Salk Inst For Biological Studi Mutated fibroblast growth factor (fgf) 1 and methods of use
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
JP2018535964A (ja) 2015-10-30 2018-12-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
US11746352B2 (en) * 2019-12-30 2023-09-05 Eligo Bioscience Microbiome modulation of a host by delivery of DNA payloads with minimized spread
US12098372B2 (en) 2019-12-30 2024-09-24 Eligo Bioscience Microbiome modulation of a host by delivery of DNA payloads with minimized spread

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692435A (en) * 1978-11-06 1987-09-08 Choay, S.A. Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
IL72058A (en) * 1984-06-08 1988-03-31 Ram Lavie Method for heat and mass exchange operations
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4686113A (en) * 1985-12-18 1987-08-11 Fairchild Semiconductor Corporation Plasma confinement in a low pressure electrically grounded R.F. heated reactor and deposition method
US5827826A (en) * 1986-03-03 1998-10-27 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compositions of human endothelial cell growth factor
ZA874487B (en) * 1986-06-23 1987-12-23 Merck & Co.,Inc. Novel hmg-coa reductase inhibitors
CA1322163C (en) * 1986-07-03 1993-09-14 Kenneth A. Thomas, Jr. Plasminogen activator production
US5045565A (en) * 1987-03-09 1991-09-03 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
FR2663639B1 (fr) * 1990-06-26 1994-03-18 Rhone Poulenc Sante Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6086582A (en) * 1997-03-13 2000-07-11 Altman; Peter A. Cardiac drug delivery system
AU8855798A (en) * 1997-07-03 1999-01-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel composition for treating, preventing and/or delaying ischemic cell death
DE69838526T2 (de) * 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Gerät zum Freisetzen eines Medikaments im Herzen
US20020122792A1 (en) * 1998-07-24 2002-09-05 Thomas J. Stegmann Induction of neoangiogenesis in ischemic myocardium
US6102887A (en) * 1998-08-11 2000-08-15 Biocardia, Inc. Catheter drug delivery system and method for use
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
US20020037508A1 (en) * 2000-01-19 2002-03-28 Michele Cargill Human single nucleotide polymorphisms
US6988004B2 (en) * 2000-05-16 2006-01-17 Bioheart, Inc. Method for inducing angiogenesis by electrical stimulation of muscles
KR100861240B1 (ko) * 2000-08-15 2008-10-02 카디오배스큘러 바이오 떼러퓨틱스, 인크. 생물학적으로 활성인 인간 산성 섬유아세포 성장인자의제조방법과 맥관형성 촉진을 위한 그 용도
AU2640002A (en) * 2000-12-07 2002-06-18 Aventis Pharma Sa Sequences upstream of the carp gene, vectors containing them and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2573896C2 (ru) * 2009-10-15 2016-01-27 Дженентек, Инк. Химерные факторы роста фибробластов с измененной рецепторной специфичностью

Also Published As

Publication number Publication date
AU2010257389A1 (en) 2011-01-27
NO20060032L (no) 2006-01-04
KR20060052692A (ko) 2006-05-19
JP2006526592A (ja) 2006-11-24
CA2526792A1 (en) 2004-12-16
NZ543717A (en) 2008-06-30
EA009390B1 (ru) 2007-12-28
US20050096286A1 (en) 2005-05-05
EP1677831A1 (en) 2006-07-12
AU2004244756A1 (en) 2004-12-16
BRPI0410844A (pt) 2006-06-27
WO2004108167A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
EA200501846A1 (ru) Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
EP1765362A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOVASCULAR DISEASES
DE60132343D1 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
DK1187918T4 (da) TEK-antagonister
DE69636764D1 (de) Zusammensetzungen zur behandlung von ischamischem gewebe
DE60100740D1 (de) Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60143078D1 (de) Pax2 zur behandlung von nierenkrankheiten
EA200601359A1 (ru) Применение эритропоэтина в низкой дозировке для стимуляции эндотелиальных клеток-предшественников, а также для регенерации органов и замедления прогрессирования повреждений конечных органов
ATE491715T1 (de) Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
JP2003528919A5 (enExample)
DE60116075D1 (de) Behandlung von tumoren mit photodynamischer therapie
DE60319135D1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
DE60020729D1 (de) Verfahren und zusammensetzung zur behandlung von adenovirale augeninfektionen
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
ATE324905T1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
CY1109771T1 (el) Η χρηση της φορμοτερολης στην προφυλακτικη και/ή θεραπευτικη αντιμετωπιση της μυικης απωλειας και/ή του καχεκτικου συνδρομου τα οποια συνδεονται με τις καταβολικες συνθηκες ορισμενων παθησεων. οπως ο καρκινος, to aids, οι μολυνσεις, ο διαβητης και αλλες
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
WO2006091729A3 (en) Revascularization of ischemic retinal tissue and screening method therefor
WO2006128179A3 (en) Use of matrilin-1 for the treatment of angiogenesis related diseases

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU